Mandana Khodashahi

Dr. Mandana Khodashahi


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 August 2016 in Electronic Physiciane
Verified
Journal Article
Open access
ZSZhaleh Shariati Sarabi
Zhaleh Shariati Sarabi
MSMehran Ghazi Saeidi
Mehran Ghazi Saeidi
MKMandana Khodashahi
Mandana Khodashahi
ARAli Etemad Rezaie
Ali Etemad Rezaie
KHKamila Hashemzadeh
Kamila Hashemzadeh
HHHossein Heidari
Hossein Heidari
Evaluation of the Anti-inflammatory Effects of Atorvastatin on Patients with Rheumatoid Arthritis: A Randomized Clinical Trial

2 January 2019 in Inflammopharmacology
Verified
Journal Article
Closed access
ZRZahra Rezaieyazdi
Zahra Rezaieyazdi
AFAbid Farooqi
Abid Farooqi
HSHossein Soleymani-Salehabadi
Hossein Soleymani-Salehabadi
AAArman Ahmadzadeh
Arman Ahmadzadeh
MAMona Aslani
Mona Aslani
AMAbbas Mirshafiey
Abbas Mirshafiey

25 December 2017 in Electronic Physiciane
Verified
Journal Article
Open access
MSMassoud Saghafi
Massoud Saghafi
MKMandana Khodashahi
Mandana Khodashahi
NSNayyereh Saadati
Nayyereh Saadati
AAAzita Azarian
Azita Azarian
ZRZahra Rezaieyazdi
Zahra Rezaieyazdi
MSMaryam Sahebari
Maryam Sahebari
Relationship between cartilage oligomeric matrix protein (COMP) and rheumatoid arthritis severity

25 May 2019 in Iranian Journal of Psychiatry
Verified
Journal Article
Open access
MSMaryam Sahebari
Maryam Sahebari
MEMohammad Javad Asghari Ebrahimabad
Mohammad Javad Asghari Ebrahimabad
ASAli Ahmadi Shoraketokanlo
Ali Ahmadi Shoraketokanlo
HSHamidreza Aghamohammadian Sharbaf
Hamidreza Aghamohammadian Sharbaf
MKMandana Khodashahi
Mandana Khodashahi
Objective: The aim of this study was to evaluate the efficacy of acceptance and commitment therapy (ACT) in the reduction of disappointment, psychological distress, and psychasthenia among patients with systemic lupus erythematosus (SLE). Method: This quasi-experimental study was conducted on 24 females with lupus who referred to the Rheumatoid Disease Research Center (RDRC) of Ghaem hospital in Mashhad, Iran. This study had a pretest-posttest control group design. The participants were randomly assigned into 2 groups of experimental and control. The experimental group was treated with ACT. Data were collected using the Beck’s Hopelessness Scale, Kessler’s Psychological Distress Inventory, and Krupp’s Psychasthenia Inventory. Results: Mean age and mean duration of illness were 37.25±4.61 and 5.12±2.33 years, respectively. The mean disappointment score and psychological distress in the experimental group were lower compared to those in control group at the post experimental stage (P<0.001). Moreover, there was a significant difference between the experimental and control groups in the mean scores of psychasthenia in the posttest stage (P<0.001). Conclusion: According to the obtained results of this study, the enhancement of psychological flexibility based on ACT positively affected disappointment, psychological distress, and psychasthenia among the lupus patients. Therefore, it can be concluded that this therapeutic approach could reduce psychasthenia in patients through clarification of the values.

3 September 2019 in European Journal of Rheumatology
Verified
Journal Article
Open access
MSMaryam Sahebari
Maryam Sahebari
ZRZahra Rezaieyazdi
Zahra Rezaieyazdi
SHSeyed Isaac Hashemy
Seyed Isaac Hashemy
SKSahar Khorasani
Sahar Khorasani
SSSanaz Shahgordi
Sanaz Shahgordi
MKMandana Khodashahi
Mandana Khodashahi
Objective: The present study aimed to determine the relationship between the serum hepcidin level and disease activity in patients with rheumatoid arthritis (RA). Methods: This study was conducted on 80 patients with RA (36 cases with anemia of chronic disease [ACD] and 44 patients without ACD). Disease activity was measured by the 28-joint Disease Activity Score based on the erythrocyte sedimentation rate (DAS28-ESR). According to the DAS28-ESR score, 52 and 28 cases were categorized as inactive to moderately active RA (DAS28-ESR≤5.1) and highly active RA (DAS28-ESR>5.1), respectively. In addition, the serum hepcidin level was evaluated in all patients to determine its correlation with the DAS28-ESR score. Results: There was no significant difference between the RA with ACD and RA without ACD groups in terms of the median (interquartile range) hepcidin level (1207 [985.2] vs. 923.8 [677.3] ng/mL; P=0.57). Likewise, no significant difference was observed between the active RA and inactive to moderately active RA groups in this regard (1131.8 [991.3] vs. 1090.9 [631.4] ng/mL; P=0.53). Conclusion: Hepcidin has no association with disease activity in RA. Therefore, it is not necessary to measure hepcidin to determine the RA activity. Cite this article as: Sahebari M, Rezaieyazdi Z, Hashemy SI, Khorasani S, Shahgordi S, Alizadeh MK, et al. Serum hepcidin level and rheumatoid arthritis disease activity. Eur J Rheumatol 2019; 6(2): 73-7.

1 March 2021
Verified
Journal Article
Open access
KHKamila Hashemzadeh
Kamila Hashemzadeh
MFMaryam Fatemipour
Maryam Fatemipour
SMSeyede Zahra Mirfeizi
Seyede Zahra Mirfeizi
MJMohammadhasan Jokar
Mohammadhasan Jokar
ZSZhaleh Shariati Sarabi
Zhaleh Shariati Sarabi
MKMandana Khodashahi
Mandana Khodashahi
Objectives: This study aims to determine the relationship between the severity of sarcoidosis and serum B cell activating factor (BAFF) concentrations. Patients and methods: This cross-sectional study was conducted between December 2015 and March 2018 on 55 patients with sarcoidosis (16 males, 39 females; mean age: 39.9; range, 25 to 60 years) and 28 healthy subjects (7 males, 20 females; mean age: 39; range, 25 to 60 years). The sarcoidosis patients were divided into active chronic sarcoidosis and acute sarcoidosis groups. The diagnosis of sarcoidosis was based on clinical, radiological, and pathologic findings. Also, the diagnosis of the active disease was based on the level of angiotensin-converting enzyme, active skin, eye, and lung lesions. Scadding score was also measured, and other patient information was collected by pre-designed questionnaires. Results: The most involved organs were the skin (92.7%) and joints (92.3%), respectively. The mean BAFF concentration in both active chronic sarcoidosis (p=0.001) and acute sarcoidosis (p=0.001) groups was significantly higher than the control group, but the mean level of BAFF in these two groups was not significantly different (p=0.351). Between two groups of patients, only calcium (p=0.001) and forced vital capacity (p=0.021) were higher in the acute group of sarcoidosis. Also, among the factors associated with active chronic sarcoidosis and acute sarcoidosis, none was significantly correlated with BAFF. Conclusion: Serum BAFF concentration was higher in patients with sarcoidosis, while this was not significantly different from increasing severity of symptoms. There was no significant difference in BAFF levels between acute sarcoidosis and active chronic types.